Form 4: VYNE CSO Sells Shares for Tax Obligations

VYNE Therapeutics' Chief Scientific Officer, Iain Stuart, disposed of 2,448 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Iain Stuart, Chief Scientific Officer of VYNE Therapeutics Inc., reported a transaction involving the company's common stock.
• On December 31, 2025, Stuart disposed of 2,448 shares of common stock.
• The disposition was a 'tax withholding' transaction, meaning shares were withheld by the Issuer to satisfy tax requirements upon the vesting of restricted stock units.
• The price per share for the disposed securities was $0.5801.
• Following this transaction, Stuart beneficially owns 115,239 shares of VYNE Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary tax withholding related to RSU vesting, which is a neutral event and does not reflect positive or negative sentiment towards the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction (Form 4) reporting the disposition of shares for tax withholding purposes, which is a common occurrence when restricted stock units (RSUs) vest for executives. It does not reflect a discretionary sale based on market sentiment or company performance, nor does it indicate broader industry trends.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or a significant shift in ownership.

Key Dates

Keywords

VYNE Therapeutics, VYNE, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Iain Stuart, Chief Scientific Officer